Eversept Partners’s Celldex Therapeutics CLDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-191,600
Closed -$5.17M – 76
2022
Q2
$5.17M Buy
+191,600
New +$5.56M 0.37% 46

Other funds holding CLDX

Eversept Partners's CLDX Position: Q3 2026 in Review

Eversept Partners reduced its Celldex Therapeutics (CLDX) stake by 34% in Q3 2026, selling an estimated $23.4M and leaving 1,174,771 shares worth $38.1M. The position accounts for 2.05% of the portfolio, ranked #13.

Eversept Partners first reported a position in CLDX in Q2 2020 and has held it in 22 quarters since. The position peaked at $66.5M in Q2 2026. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Eversept Partners held 1,174,771 shares of Celldex Therapeutics worth $38.1M as of Q3 2026.
  • Eversept Partners sold 611,170 Celldex Therapeutics shares in Q3 2026, an estimated $23.4M.
  • Celldex Therapeutics made up 2.05% of Eversept Partners's portfolio in Q3 2026, its #13 holding.
  • Eversept Partners first reported a position in Celldex Therapeutics in Q2 2020 and has held it in 22 quarters since.
  • Eversept Partners's Celldex Therapeutics position peaked at $66.5M in Q2 2026.
  • 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Eversept Partners's 13F filing for Q3 2026, filed 16 Nov 2026.